First patient dosed in Ph 1/2 trial of ARV-6723 in advanced solid tumors
“The advancement of ARV-6723 into the clinic represents an important step in expanding the application of targeted protein degradation into immuno-oncology,” said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. “Resistance to immunotherapy remains a significant challenge; to date, combinations targeting other immune pathways have not provided a reliable way to prevent or reverse it. The encouraging preclinical data for ARV-6723 – including activity in models resistant to immune checkpoint inhibitors – support clinical investigation of its potential to address this unmet need for patients.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the